LAVAL, QUEBEC, Oct 16, 2008 — Warnex Inc. (CA:WNX: news, chart, profile) announced today that its Bioanalytical Services division has acquired two state-of-the-art TSQ Vantage mass spectrometers from Thermo Fisher Scientific Inc.

“We are pleased to be the first CRO in Canada to acquire the new TSQ Vantage system,” said Mark Busgang, President and CEO of Warnex. “Warnex strives to be at the forefront of technology in order to offer our customers the most advanced services available. The increased sensitivity of this new generation of systems will allow us to detect our customers’ compounds at very low quantitation levels with great precision.”

The TSQ Vantage system delivers up to 10 times more sensitivity than any other triple quadrupole instrument on the market and does not produce a commensurate increase in noise. New technical breakthroughs have given the TSQ Vantage unmatched signal-to-noise performance, providing better reproducibility and precision in the quantitative analysis of small molecules, biomolecules and peptides.

Warnex Bioanalytical Services offers a range of services to the pharmaceutical and biotechnology industries, specializing in bioavailability and bioequivalence studies. A scientific team of specialists in research and development, method development and validation, production, and quality assurance, supports companies in their drug development programs by carrying out analyses generated throughout the program, beginning with pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. Support to the generic drug industry is provided by analyzing physiological fluid samples obtained from clinical studies in humans to determine whether the new formulations are bioequivalent to the marketed product.